The authors used time-course RNA-seq to map SRSF1-dependent splicing changes across hours after perturbation. They report experimental validation of 67 of 143 alternative-splicing events selected for follow-up, a validation rate the study team presents as substantial given the scope of the screen. Among the validated set, 44 events were not present in GENCODE annotations; the authors specifically note 15 events that introduce previously unannotated exons. Short, declarative assays backed the claim that loss or gain of SRSF1 produces isoform switching in genes implicated in DNA repair and checkpoint control. The paper does not provide further genome-wide quantitation beyond these validated examples in the abstract.
Some SRSF1-regulated splicing events were conserved across cellular contexts. Investigators observed concordant regulation for 35 events in HEK293 and in breast and prostate cancer cell lines. That cross-model overlap suggests certain SRSF1 targets are regulated similarly in transformed and non-transformed backgrounds. The authors emphasize replication across these three models for a subset of events, while also reporting many events that appear cell-type restricted; the abstract does not enumerate those nonconcordant events in detail.
SRSF1 overexpression altered both the amount and the phosphorylation state of p53 protein. The study team observed reduced total p53 alongside increased basal phosphorylation at Ser15. Functionally, SRSF1 overexpression increased apoptosis under baseline conditions and after cisplatin exposure, but the same manipulation did not increase apoptosis following doxorubicin treatment. The authors connect a portion of validated splicing changes—17 events across 16 genes—to effects on p53 regulation or p53-dependent functions, indicating a molecular route by which SRSF1 may influence genome-maintenance pathways. The preprint text does not report the precise assays, antibody clones, or quantitative fold-changes in the abstract; those methodological details would be found in the full manuscript.
Beyond splicing, the authors report a transcriptional activation program linked to SRSF1. They identified increased transcription of 28 genes after SRSF1 perturbation, and 18 of those genes showed concordant upregulation across the same cellular models used for splicing validation. The study team frames these transcriptionally induced genes as associated with cellular signaling and organization. The abstract does not list all 28 genes or provide pathway enrichment statistics in this summary; readers must consult the full dataset for gene-level detail and statistical thresholds.
Mechanistic experiments tied SRSF1-dependent transcriptional activation to the mobilization of P-TEFb from the 7SK snRNP, a regulator of P-TEFb availability for RNA polymerase II elongation. The authors report that SRSF1 increases the pool of active P-TEFb available to stimulate transcriptional elongation, implying a direct route from an RNA-binding splicing factor to control of transcriptional output. The abstract does not specify the biochemical assays used to demonstrate P-TEFb release, nor does it provide the experimental details on how 7SK snRNP components were interrogated; these specifics are presented in the full preprint.
The authors position their work as identifying two concurrent SRSF1-regulated modules: transcriptional activation of genes tied to signaling and organization, and alternative splicing events that modulate genome-maintenance and p53-regulatory genes. They validated a defined subset of events from a larger screen and provided mechanistic links to P-TEFb dynamics. This manuscript is a bioRxiv preprint and has not been peer-reviewed; the authors and readers should treat the reported findings as provisional pending formal review. The abstract does not report full methodological parameters — for example, sample sizes, exact time points, and statistical thresholds — so readers should consult the full text for experimental design and quantitative results.